DAVID BOEL: Open Payments
NPI 1780091793 · NEPHI, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,033 in 44 payments from 10 companies in 2025. Trend: 2023 $505 · 2024 $546 · 2025 $1,033
Food & beverage: $914Education: $119
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $272 |
| Neurocrine BioSciences, Inc. | 8 | $177 |
| Alkermes, Inc. | 8 | $145 |
| Axsome Therapeutics, Inc. | 4 | $111 |
| Braeburn Inc. | 2 | $88 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $81 |
| ABBVIE INC. | 4 | $66 |
| Lundbeck LLC | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 2 | $29 |
| Indivior Inc. | 1 | $21 |
Products named: INGREZZA, AUSTEDO XR, ARISTADA, Auvelity, BRIXADI, CAPLYTA, VRAYLAR, REXULTI.
Industry payments across UT — which companies pay providers there.
